Associated Papers
Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.
Wen Y et al.
Nature Communications, 2024
Inhibition and degradation of NRAS with a pan-NRAS monobody.
Whaby M et al.
Oncogene, 2024
K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins.
Magits W et al.
The Embo Journal, 2024
38858602 (PubMed )
Supplement: 44318_2024_146_MOESM1_ESM.pdf
Identification and analysis of oncogenic non-synonymous single nucleotide polymorphisms in the human NRAS gene: An exclusive in silico study.
Mozibullah M et al.
Journal, Genetic Engineering & Biotechnology, 2024
38797553 (PubMed )
Supplement: mmc1.xlsx › Table_1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing.
Youssef O et al.
World Journal of Gastroenterology, 2017
Select a paper to view details